Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC vaccine plus regular treatment for gastric cancer after surgery
ChiCTR1800015508Phase 2Not yet recruiting
- Sponsor
- Lanzhou University
- Start
- May 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in gastric cancer (GC) (2 arms), sponsored by Lanzhou University. Primary endpoints: overall survival at 5 years and progression-free survival at 5 years. Planned start May 2018; status: not yet recruiting.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800015508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015508.